Onward Medical N.V./ADR
No SEC Form 4 filings for $ONWRY in the last 30 days.
See all $ONWRY insider activity →ONWARD Medical (ONWRF) began its EIGER study, the first implant of the ARC-IM System for chronic spinal cord injury (SCI) patients. The study, with up to 12 participants, aims to assess safety and preliminary effectiveness in restoring mobility. The first procedure was performed in Switzerland. ONWRF's stock is up 2.67%, trading at EUR 2.49.
Groundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface ( BCI ) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
Over the past 7 days, alphai's AI scored 1 news story mentioning ONWRY (Onward Medical N.V./ADR). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ONWRY coverage spans financial news and technology.
ONWARD Medical (ONWRF) began its EIGER study, the first implant of the ARC-IM System for chronic spinal cord injury (SCI) patients. The study, with up to 12 participants, aims to assess safety and preliminary effectiveness in restoring mobility. The first procedure was performed in Switzerland. ONWRF's stock is up 2.67%, trading at EUR 2.49.
ONWARD Medical's recent successful BCI implants reinforce its leadership position in the emerging neurotechnology sector. The company's ARC-BCI Therapy aims to restore movement after spinal cord injuries, which could lead to increased investor confidence and potential stock appreciation.
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
NEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- OTC Markets Group Inc.
alphai scores every news story that mentions ONWRY with an AI model for sentiment and relevance, and aggregates insider trades from Onward Medical N.V./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
ONWARD Medical (ONWRF) began its EIGER study, the first implant of the ARC-IM System for chronic spinal cord injury (SCI) patients. The study, with up to 12 participants, aims to assess safety and preliminary effectiveness in restoring mobility. The first procedure was performed in Switzerland. ONWRF's stock is up 2.67%, trading at EUR 2.49.
2 min readGroundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface ( BCI ) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities
2 min readSponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
2 min readNEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- OTC Markets Group Inc.
2 min read
